These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 16493198

  • 21. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease.
    Rulyak SJ, Saunders MD, Lee SD.
    J Clin Gastroenterol; 2003 Mar; 36(3):234-7. PubMed ID: 12590235
    [Abstract] [Full Text] [Related]

  • 22. The continuous rediscovery and the benefit-risk ratio of thioguanine, a comprehensive review.
    Bayoumy AB, Simsek M, Seinen ML, Mulder CJJ, Ansari A, Peters GJ, De Boer NK.
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):111-123. PubMed ID: 32090622
    [Abstract] [Full Text] [Related]

  • 23. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.
    Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK.
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):291-4. PubMed ID: 20922194
    [Abstract] [Full Text] [Related]

  • 24. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
    Almer SH, Hjortswang H, Hindorf U.
    Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369
    [Abstract] [Full Text] [Related]

  • 25. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease.
    Teml A, Schwab M, Hommes DW, Almer S, Lukas M, Feichtenschlager T, Florin T, Seiderer J, Petritsch W, Bokemeyer B, Kreisel W, Herrlinger KR, Knoflach P, Bonaz B, Klugmann T, Herfarth H, Pedarnig N, Reinisch W.
    Wien Klin Wochenschr; 2007 Mar; 119(17-18):519-26. PubMed ID: 17943403
    [Abstract] [Full Text] [Related]

  • 26. Further experience with the use of 6-thioguanine in patients with Crohn's disease.
    Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J.
    Inflamm Bowel Dis; 2008 Oct; 14(10):1399-405. PubMed ID: 18521912
    [Abstract] [Full Text] [Related]

  • 27. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
    Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V.
    Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
    [Abstract] [Full Text] [Related]

  • 28. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM, Ward MG, Blaker PA, Sparrow MP.
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
    [Abstract] [Full Text] [Related]

  • 29. Limited intra-individual variability in hypoxanthine-Guanine phosphoribosyl transferase, thiopurine S-methyl transferase, and xanthine oxidase activity in inflammatory bowel disease patients during 6-thioguanine therapy.
    van Asseldonk DP, de Boer NK, Smid K, Mulder CJ, van Bodegraven AA, Peters GJ.
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):284-90. PubMed ID: 20544508
    [Abstract] [Full Text] [Related]

  • 30. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA.
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [Abstract] [Full Text] [Related]

  • 31. Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide.
    Crouwel F, Simsek M, Mulder CJ, Buiter HJ, De Boer NK.
    J Gastrointestin Liver Dis; 2020 Dec 13; 29(4):637-645. PubMed ID: 33331335
    [Abstract] [Full Text] [Related]

  • 32. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Derijks LJ, Gilissen LP, de Boer NK, Mulder CJ.
    J Hepatol; 2006 Apr 13; 44(4):821-2. PubMed ID: 16487623
    [No Abstract] [Full Text] [Related]

  • 33. Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?
    Movva R, Haywood A, Khan SA, Florin TH, Oancea I.
    J Dig Dis; 2017 Sep 13; 18(9):529-536. PubMed ID: 28834232
    [Abstract] [Full Text] [Related]

  • 34. Review article: thiopurines in inflammatory bowel disease.
    Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):715-29. PubMed ID: 16918876
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    van Asseldonk DP, Simsek M, de Boer NKH, Jharap B, Bloemena E, den Hartog G, Westerveld DB, Becx MC, Russel MG, Lissenberg-Witte BI, van Nieuwkerk CM, Mulder CJJ, Verheij J, van Bodegraven AA.
    Scand J Gastroenterol; 2019 Jun 01; 54(6):753-760. PubMed ID: 31203688
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun 01; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 40. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease.
    Gupta P, Gokhale R, Kirschner BS.
    J Pediatr Gastroenterol Nutr; 2001 Oct 01; 33(4):450-4. PubMed ID: 11698762
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.